Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages
The benefits of engaging a CMO or CDMO for antibody development and production extend beyond fulfilling the needs of small companies; access to new technologies and operational flexibility are attractive attributes to larger players as well
More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are over 25 technology platforms available for use in therapy development efforts
More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Analysis
More than 80 companies presently claim to have the required expertise to design and manufacture different types of labels, using both conventional and advanced printing methods, for use in medical devices, claims Roots Analysis
Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption.
Advances in information technology and biomedical science have enabled the development of digital solutions for biomarkers, which, owing to the myriad of pertinent applications, are being increasingly adopted in modern healthcare practices